Evidence-based management of non-alcoholic fatty liver disease
Abstract
Non-alcoholic fatty liver disease (NAFLD)it is the commonest cause of chronic liver disease in developed countries and is rapidly increasing in the Asia-Pacific region. NAFLD has important long term health implications. There is increased overall mortality most commonly from cardiovascular disease, and also increased liver-related mortality. Treatment options available for NAFLD include general measures at managing obesity and correcting the metabolic syndrome and liver-directed therapies aimed at reducing the liver inflammation and hepatocellular injury. This article reviews the current evidence based management of NAFLD and associated metabolic comorbidities.
Sri Lanka Journal of Diabetes, Endocrinology and Metabolism 2015; 5: 28-33
© 2015 S. K. Kodisinghe, M. A. Niriella, published by Sri Lanka College of Endocrinologists
This work is licensed under the Creative Commons License.